Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

Conclusions This is the first BTKi-integrated safety analysis that includes patients with MS. Overall, evobrutinib treatment (all doses) was generally well tolerated across indications. Trial registration numbers NCT02975349, NCT03233230, NCT02975336.

http://jnnp.bmj.com/cgi/content/short/94/1/1?rss=1

Source: Journal of Neurology, Neurosurgery and Psychiatry - December 14, 2022 Category: Neurosurgery Authors: Montalban, X., Wallace, D., Genovese, M. C., Tomic, D., Parsons-Rich, D., Le Bolay, C., Kao, A. H., Guehring, H. Tags: Open access Multiple sclerosis Source Type: research